Morgan Stanley Upgrades Haleon (NYSE:HLN) to Overweight

Haleon (NYSE:HLN) was upgraded by stock analysts at Morgan Stanley from an “equal weight” rating to an “overweight” rating in a report issued on Friday, Marketbeat Ratings reports. The firm currently has a $11.25 price objective on the stock. Morgan Stanley’s price objective suggests a potential upside of 4.65% from the company’s previous close.

A number of other equities research analysts have also weighed in on the company. HSBC reaffirmed a “hold” rating on shares of Haleon in a research report on Wednesday, March 5th. Barclays restated an “overweight” rating on shares of Haleon in a report on Tuesday. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Haleon in a report on Monday, March 3rd. Finally, Hsbc Global Res lowered shares of Haleon from a “strong-buy” rating to a “hold” rating in a report on Wednesday, March 5th. Five investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Haleon presently has a consensus rating of “Moderate Buy” and an average price target of $11.25.

Haleon Trading Up 1.7 %

NYSE HLN opened at $10.75 on Friday. The stock has a market cap of $48.48 billion, a PE ratio of 31.62, a PEG ratio of 2.82 and a beta of 0.24. Haleon has a 12 month low of $8.24 and a 12 month high of $10.85. The company’s 50-day moving average price is $10.20 and its 200-day moving average price is $9.84. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44.

Haleon (NYSE:HLN) last issued its earnings results on Thursday, February 27th. The company reported $0.05 EPS for the quarter. Haleon had a net margin of 10.85% and a return on equity of 14.76%. The business had revenue of $3.54 billion for the quarter, compared to the consensus estimate of $3.38 billion. Equities research analysts forecast that Haleon will post 0.43 earnings per share for the current year.

Institutional Trading of Haleon

Hedge funds have recently modified their holdings of the company. Baker Tilly Wealth Management LLC lifted its position in Haleon by 13.6% during the fourth quarter. Baker Tilly Wealth Management LLC now owns 67,384 shares of the company’s stock valued at $643,000 after acquiring an additional 8,079 shares during the last quarter. Fiduciary Alliance LLC acquired a new position in shares of Haleon during the fourth quarter worth $112,000. PFW Advisors LLC purchased a new stake in shares of Haleon during the 4th quarter valued at $99,000. Marcum Wealth LLC boosted its position in shares of Haleon by 19.7% in the 4th quarter. Marcum Wealth LLC now owns 24,714 shares of the company’s stock worth $236,000 after purchasing an additional 4,074 shares in the last quarter. Finally, SeaCrest Wealth Management LLC purchased a new position in Haleon during the 4th quarter worth $102,000. 6.67% of the stock is owned by hedge funds and other institutional investors.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.